These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 56538)
61. Ribose-cysteine and levodopa abrogate Parkinsonism via the regulation of neurochemical and redox activities in alpha-synuclein transgenic Idowu OK; Oremosu AA; Dosumu OO; Mohammed AA Fly (Austin); 2024 Dec; 18(1):2306687. PubMed ID: 38286464 [TBL] [Abstract][Full Text] [Related]
62. Exploring the Central Mechanisms of Botulinum Toxin in Parkinson's Disease: A Systematic Review from Animal Models to Human Evidence. Cutrona C; Marchet F; Costanzo M; De Bartolo MI; Leodori G; Ferrazzano G; Conte A; Fabbrini G; Berardelli A; Belvisi D Toxins (Basel); 2023 Dec; 16(1):. PubMed ID: 38251226 [TBL] [Abstract][Full Text] [Related]
63. The Neuropharmacological Evaluation of Seaweed: A Potential Therapeutic Source. Jannat K; Balakrishnan R; Han JH; Yu YJ; Kim GW; Choi DK Cells; 2023 Nov; 12(22):. PubMed ID: 37998387 [TBL] [Abstract][Full Text] [Related]
64. Cholinergic relevant functional reactivity is associated with dopamine responsiveness of tremor in Parkinson's disease. Wu J; Zhou C; Guo T; Guan X; Gao T; Bai X; Wu H; Chen J; Wen J; Liu X; Gu L; Song Z; Xuan M; Gu Q; Huang P; Pu J; Zhang B; Xu X; Zhang M Brain Imaging Behav; 2022 Jun; 16(3):1234-1245. PubMed ID: 34973120 [TBL] [Abstract][Full Text] [Related]
65. Extracellular Vesicles for the Diagnosis and Treatment of Parkinson's Disease. Upadhya R; Shetty AK Aging Dis; 2021 Sep; 12(6):1438-1450. PubMed ID: 34527420 [TBL] [Abstract][Full Text] [Related]
66. Decreased Exosomal Acetylcholinesterase Activity in the Plasma of Patients With Parkinson's Disease. Shim KH; Go HG; Bae H; Jeong DE; Kim D; Youn YC; Kim S; An SSA; Kang MJ Front Aging Neurosci; 2021; 13():665400. PubMed ID: 34122043 [TBL] [Abstract][Full Text] [Related]
73. A network model of basal ganglia for understanding the roles of dopamine and serotonin in reward-punishment-risk based decision making. Balasubramani PP; Chakravarthy VS; Ravindran B; Moustafa AA Front Comput Neurosci; 2015; 9():76. PubMed ID: 26136679 [TBL] [Abstract][Full Text] [Related]
75. A role of the polysynaptic system of substantia nigra in the cholinergic-dopaminergic equilibrium in the central nervous system. Wolfarth S; Dulska E; Gołembiowska-Nikitin K; Vetulani J Naunyn Schmiedebergs Arch Pharmacol; 1978 Apr; 302(2):123-31. PubMed ID: 652058 [No Abstract] [Full Text] [Related]
76. Aetiology and natural history of Parkinson's disease. Pearce JM Br Med J; 1978 Dec; 2(6153):1664-6. PubMed ID: 32952 [No Abstract] [Full Text] [Related]
77. Evidence for a change in neurotransmitter affecting oesophageal motility in Parkinson's disease. Bramble MG; Cunliffe J; Dellipiani AW J Neurol Neurosurg Psychiatry; 1978 Aug; 41(8):709-12. PubMed ID: 28387 [TBL] [Abstract][Full Text] [Related]
78. The biochemistry of the basal ganglia and Parkinson's disease. Curzon G Postgrad Med J; 1977 Dec; 53(626):719-25. PubMed ID: 24209 [TBL] [Abstract][Full Text] [Related]
79. Dopamine acetylcholine imbalance in Parkinson's disease. Possible regenerative overgrowth of cholinergic axon terminals. Spehlmann R; Stahl SM Lancet; 1976 Apr; 1(7962):724-6. PubMed ID: 56538 [TBL] [Abstract][Full Text] [Related]
80. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Zhou FM; Wilson C; Dani JA Neuroscientist; 2003 Feb; 9(1):23-36. PubMed ID: 12580337 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]